MAPT and supranuclear palsy, progressive, 1: The study, which used semiquantification correlated with visualization, emphasized that the selective binding capacity of [18F]PI-2620 could detect primary tauopathy diseases such as progressive supranuclear palsy (PSP) [8], which is associated with significant tau deposition in the globus pallidus, midbrain, and basal ganglia [26].